Skip to main content

Oxilio and Quotient Sciences Announce Regulatory Approval for Oxilio’s OXL001 Development Program

News & Announcements , Customer Milestone , Translational Pharmaceutics®

Oxilio and Quotient Sciences Announce Regulatory Approval for Oxilio’s OXL001 Development Program

Oxilio and QS partnership

NOTTINGHAM, UK; September 29th, 2022 – Oxilio, a pioneering drug development company repurposing existing drugs to address unmet needs in cancer treatment, and Quotient Sciences, a drug development and manufacturing accelerator, today announced an update on the development of Oxilio’s OXL001 product.

Oxilio is pleased to announce that it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee (REC) for its first Clinical Trial Application (CTA) with OXL001. Following initial formulation development by Oxilio in collaboration with its partner company, TRx Biosciences, Quotient Sciences’ integrated Translational Pharmaceutics® platform has been used to carry out the technical transfer and scale-up activities associated with this program and will continue to be used to support clinical trial material manufacturing and the investigation of the pharmacokinetics and safety of OXL001 in healthy volunteers.

Mark Egerton, Ph.D., CEO of Quotient Sciences, said: “We are delighted to be able to continue to assist Oxilio with their OXL001 program. By leveraging our unique, integrated Translational Pharmaceutics platform, Oxilio will have the flexibility to adjust doses based on emerging clinical data within their study, enabling us to improve their likelihood of success, reduce their development time, and ultimately get new medicines to patients faster.”

Dr. Simon Yaxley, Director of Oxilio, added: “Utilizing Quotient Sciences’ Translational Pharmaceutics platform has enabled us to successfully achieve this important milestone of receiving regulatory approval to undertake our first Phase 1 clinical trial with OXL001. We look forward to commencing this study within the next few weeks.


About Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast. For more information, please visit quotientsciences.com.

About Oxilio

Oxilio is a pioneering pharmaceutical drug development company improving cancer treatment through rapid, cost-effective drug development. Our mission is to identify, repurpose, and commercialize existing drugs to address unmet needs in cancer therapy. We find new uses for old drugs, a proven approach that involves less risk, time, and cost to bring a drug to the marketplace. Through repurposing, reformulation, and gold-standard modeling and simulations, we are fast-tracking disruptive drug development at speed and at low cost.

Oxilio Company Contact

[email protected]

Quotient Sciences Completes Qualification of GastroPlus® PBPK Modeling Software

News & Announcements

Quotient Sciences Completes Qualification of GastroPlus® PBPK Modeling Software

GastroPlus

Quotient Sciences’ Modeling and Simulation (M&S) team has recently completed qualification of GastroPlus, the software they use for physiologically based pharmacokinetic (PBPK) modeling. This 2-year project reflects Quotient Sciences’ commitment to conducting high-quality modeling work with regard to data integrity. In addition, this work proactively takes into account recently issued regulatory draft guidelines by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) around the conduct and reporting of PBPK modeling.

At Quotient Sciences, GastroPlus is routinely used to simulate dissolution and absorption processes and drug pharmacokinetics, in support of both integrated Translational Pharmaceutics® programs and as a stand-alone consultative service. The output from GastroPlus may be used to inform key formulation and clinical development decisions.

The GastroPlus qualification project involved collating and preparing data, building a GastroPlus database, executing drug records within the database, and analyzing the model output and performance. In total, 100 database records with a variety of different properties were compiled, and five instances of the software across different machines were evaluated. Overall, the performance of GastroPlus was shown to be qualified to predict real-life scenarios and provide reproducibility across machines. Sarah Stevens, Senior Vice President and Head of Early Development at Quotient Sciences, said, “We are delighted that the qualification of GastroPlus has been successfully completed. This important project will ensure that we continue to produce high-quality modeling data that aids in critical formulation decision-making, in order to best support our customers’ drug development programs.”

Quotient Sciences will be presenting on this project at the upcoming Pharmacokinetics UK (PKUK) conference in Canterbury Cathedral, UK, on November 2-4, where Kevser Sevim (Modeling and Simulation Research Fellow) and Alison Wilby (Director of Modeling and Simulation) will be presenting a poster entitled “Qualification of GastroPlus® Physiologically-Based Pharmacokinetic (PBPK) Modelling Software to Support Decision Making in Clinical Development”.

Get more information on Quotient Sciences’ Modeling and Simulation services.

GastroPlus® is a registered trademark of Simulations Plus.

Quotient Sciences Expands UK Facilities to Support the Delivery of Translational Pharmaceutics® Programs

News & Announcements , Translational Pharmaceutics® , Nottingham, UK , Reading, UK

Quotient Sciences Expands UK Facilities to Support the Delivery of Translational Pharmaceutics® Programs

Outside of one of Quotient Sciences' buildings in Nottingham, UK

Quotient Sciences has completed major investments and expansions at its Nottingham, UK and Reading, UK, facilities to support the delivery of fully integrated drug development programs.

Company increases laboratory and clinical capacity to meet demand for fully integrated drug development capabilities

NOTTINGHAM, UK; September 22, 2022 – Quotient Sciences, a drug development and manufacturing accelerator, has completed major investments and expansions at its Nottingham, UK and Reading, UK, facilities to support the delivery of fully integrated drug development programs through the Company’s flagship platform, Translational Pharmaceutics®.

The new clinical pharmacology space and expanded development laboratories increase the Company’s capacity to conduct integrated Translational Pharmaceutics programs for global pharma and biotech customers.

Translational Pharmaceutics integrates drug substance, drug product, and clinical testing activities under a single outsourcing provider to accelerate development timelines and reduce costs. 

Developed in consultation with the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA), the platform employs rapid “make-test” cycles, where drug products are manufactured, released, and dosed in a clinical study in days rather than months.

In Nottingham, UK, Quotient Sciences has opened a 17,000 sq ft, MHRA-inspected clinical pharmacology facility, which includes 40 beds with ancillary volunteer lounges, processing labs, a dispensary, and controlled storage. The new facility is located alongside their existing formulation development, manufacturing, and clinical operations facilities at the Company’s Nottingham campus.

At their Reading, UK site, the firm has completed a £1.5 million expansion of its early development and manufacturing facility, which has doubled its formulation development and analytical footprint at the facility, with increased office space also part of the expansion.

“Quotient Sciences’ mission is to help bring new medicines to patients faster by breaking down traditional industry silos,” stated Mark Egerton, Ph.D., CEO of Quotient Sciences.

“Our unique Translational Pharmaceutics platform was launched over 15 years ago and has accelerated the development of close to 1,000 molecules for our customers. These expansions are consistent with our overall growth strategy and in direct response to feedback from our customers and the increasing demand for our services.”


About Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast.

Gareth Jenkins Contributes to Chemistry Today Panel Discussion on Flow Chemistry

Articles & Publications , Dr. Gareth Jenkins

Gareth Jenkins Contributes to Chemistry Today Panel Discussion on Flow Chemistry

Hexagons on blue gradient background with Quotient Sciences logo

Gareth Jenkins, VP Science and Technology, Candidate Development Services at Quotient Sciences, Contributes to Chemistry Today Panel Discussion on Flow Chemistry. Read Gareth's contributions to this panel discussion with Chemistry Today July/August 2022 issue.

For what types of reactions do you consider flow chemistry most useful?

Highly energetic and very fast reactions are more easily engineered and controlled using continuous processing than in batch. Similarly, if we are looking at a process with highly hazardous material and we want to minimize the risk, continuous processing can provide that basis of safety. We recently ran a process with liquid bromine that would have been much more complex to handle safely in batch than using the very simple set-up of a couple of pumps and a flow reactor.

What are the typical scales in which continuous manufacturing processes are carried out in your organization?

Quotient Sciences is a drug development and manufacturing accelerator, so most of our chemistry projects are in very early development. Often we are looking at the first scale-up of a new drug candidate from gram to kilogram scale to support pre-clinical evaluation and Phase 1/2 clinical development. Our flow chemistry is, therefore, targeted towards making a few kilograms to a few 10s of kilograms of the active pharmaceutical ingredient (API). This means that we can keep the flow reactors very small, stay within a laboratory environment, and produce multi-kilogram quantities per day.

Are you utilizing commercial flow reactors or home-built systems?

This is one of the key advantages of flow chemistry, which can often get overlooked. The reactors themselves can be very simple. Often a piece of stainless-steel tube or an off-the-shelf static mixer is all that is needed for the reactor, and it is very easy to quickly modify to adjust for different flow rates or residence times as we develop the process. The equipment around the reactors, such as pumps, mass flow meters, and back pressure regulators, is also generally commercially available. For example, we now have a wide variety of different pumps that can be brought together for each new process we are looking at. This is where we need some chemical engineering experience within the team to help guide the selection of the best pump for the materials and flow rates we are going to need.

How important is collaboration for your organization in view of knowledge transfer and expanding skillsets in flow chemistry?

Our adoption of flow chemistry was accelerated through an Innovate UK-funded collaboration with Professor Michael George and Professor Martyn Poliakoff at the University of Nottingham, which also supported the creation of an internal ‘Flow Chemistry R&D’ team at our Alnwick site. From 2018 to 2021, this enabled us to demonstrate that flow chemistry can provide significant benefits for rapid and robust delivery of material to support pharmaceutical development, and this is now firmly embedded within our chemistry team.

Process analytical technology (PAT) and artificial intelligence (AI)-assisted methods are a growing topic this decade. Do you see advantages of implementing these technologies in flow compared with batch?

Flow reactors operate with minimal operator interventions. Flow rates are set on the pump controllers, the pressure is established using a back pressure regulator, and the temperature is established using temperature control units. As most of these process parameters can be interfaced into a process control system, it is very easy to also add PAT and use that to measure the output. The next logical step is to build a feedback loop from the outputs to control the process parameter inputs. Putting all of this into an algorithm means that it is possible to automate the screening of a variety of process parameters, such as temperature. We start with a particular residence time and reaction temperature and use an algorithm to assess what happens if we change the temperature in 5°C steps or if we change the residence time in 30-second steps. Using the very small-scale flow reactors based on narrow-bore, high-performance liquid chromatography (HPLC) tubing, it becomes very quick and material-sparing to rapidly screen a wide range of process conditions. This can help with our process understanding to identify where the edge of failure might be for a particular reaction.

What are the main barriers to wider adoption of flow chemistry in some sectors (e.g. the pharmaceutical industry)?

There has been considerable uptake in flow chemistry across the pharmaceutical industry over the past few years, with many companies establishing flow chemistry within their process development groups. With the recent ICH Q13 guidance on continuous processing close to being finalized, the perceived regulatory barrier is also much lower. Over time, we will see more APIs manufactured with at least one stage by flow chemistry.

Do you think that flow chemistry is a valuable contributor to realizing more sustainable chemistry, e.g. by reducing the carbon footprint in your organization?

Flow chemistry, especially continuous manufacturing, does have a role to play in helping to move the fine chemical and pharmaceutical industries to a more sustainable future. We have recently published an example of a chemoselective conjugate reduction by continuous hydrogenation. A heterogeneous catalyst was used in a packed bed reactor, and the continuous process demonstrated at least 8 of the 12 principles of green chemistry, scoring 77/100 using the GreenMotion metric. The biggest impact was greater selectivity, which led to less waste, a greater E-factor, and improved quality of the final product.

What challenges still remain?

One of the key advantages of early flow chemistry was the ability to access chemistry processing space that was not possible in a batch reactor, such as high-pressure/high-temperature chemistry, above the boiling point of the main solvent. This is now a well-understood reason to use flow chemistry, with many excellent examples. Two similar types of chemistry processing are photochemistry and electrochemistry, which offer novel chemistry but are very difficult to scale up using a batch reactor. There are some research-scale flow electrochemical and photochemical reactors, and it would be great to see some larger-scale equipment become available.

Read more

Emplicure AB Announce Completion of Phase I PK study for EMPLI03 with Quotient Sciences

News & Announcements

Emplicure AB Announce Completion of Phase I PK study for EMPLI03 with Quotient Sciences

Quotient Sciences logo

Emplicure AB reported dosing in the first Phase I pharmacokinetic study for EMPLI03, intended for the treatment of moderate to severe pain. The program is supported by Quotient Sciences Translational Pharmaceutics® platform.

Emplicure today reported dosing in the first pharmacokinetic study with EMPLI03, intended for the treatment of moderate to severe pain. 12 healthy subjects were given a single dose of an oral buccal tablet and blood samples were collected for analysis of Buprenorphine. Safety and tolerability were followed, and the subjects could leave the clinic after completion of the study as planned. Top line data will be available in the beginning of 2023.

The Emplicure group is developing innovative consumer and pharmaceutical products based on its proprietary bioceramic technology platform, Emplior.

EMPLI03 is being developed as an oral buccal tablet with extended release properties intended for the treatment of moderate to severe pain. The formulation is also designed to limit the potential for manipulation of the tablet for abuse. Supported by its Translational Pharmaceutics® platform Quotient Sciences has established the GMP manufacturing process of EMPLI03 and performed this first pharmacokinetic study for Emplicure.

"We have achieved one of our milestones in the development of a Buprenorphine product for the treatment of moderate to severe pain. With properties that limit abuse, EMPLI03 may contribute to a safer medical treatment", said Håkan Engqvist, CEO of Emplicure.

Pain is a major health issue globally and, in the US, as many as 20% of the population is estimated to suffer from chronic pain and in need of long-term pain relief. Widespread moderate to severe pain is a problem that is associated with high costs for society and individual patients. Opioids are, and will continue to be, an important part of pain treatment.

About Emplicure AB
Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank. Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at emplicure.com.

Read Emplicure's Announcement

About Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast. For more information, please visit quotientsciences.com.

Quotient Sciences Completes Major Expansion of Drug Substance Manufacturing Facility

Acquisitions & Growth , Alnwick , Translational Pharmaceutics®

Quotient Sciences Completes Major Expansion of Drug Substance Manufacturing Facility

Exterior photo of Quotient Sciences' Alnwick, UK facility

A £6 million project expands Quotient Sciences' Alnwick, UK into a state-of-the-art drug substance manufacturing facility that can deliver integrated support for customers from candidate selection through to early clinical development and beyond.

NOTTINGHAM, UK; October 18, 2022 – Quotient Sciences, the drug development and manufacturing accelerator, has completed the expansion of its drug substance manufacturing facility in Alnwick, UK. The £6 million project results in a state-of-the-art drug substance manufacturing capability that can deliver integrated support for customers from candidate selection through to early clinical development and beyond.  

The expansion delivers multipurpose capacity of up to 15 GMP reactor streams with reactor volumes ranging from 5 liters up to 150 liters and tactical deployment of batch or continuous flow chemistry technologies to optimize drug substance manufacturing processes. The facility has been designed adopting Industry 4.0 principles, with the inclusion of a predictive process control system (PharmaMV) improving the transfer from small-scale process research and development (PR&D) into the manufacture of multi-kilogram quantities of drug substance for clinical use.

Mark Egerton, Ph.D., CEO of Quotient Sciences, said, “Since acquiring the Alnwick facility in 2021, our objective has been to incorporate drug substance services into our integrated Translational Pharmaceutics® platform combining drug product manufacturing and clinical testing. By working with customers at the point of candidate nomination, we can now design the most streamlined programs and significantly accelerate their development timelines.”

Quotient Sciences Alnwick currently employs 200 people across a range of scientific disciplines, including process chemistry, solid-state characterization, radiosynthesis, bioanalysis, and formulation development. The company will continue to expand its capabilities, capacity, and headcount at the site to meet the growing demand for outsourced development and manufacturing services. In 2021, the site was presented an award for “Most Inspirational North East (UK) Science Employer” from STEM Learning as part of the STEM Ambassadors program. 


About Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast. For more information, please visit quotientsciences.com.

Oxilio announces start of its first clinical trial with OXL001

News & Announcements , Customer Milestone , Translational Pharmaceutics®

Oxilio announces start of its first clinical trial with OXL001

Oxilio and QS partnership

Oxford, UK; November 6th, 2022 - Oxilio, a pioneering drug development company repurposing existing drugs to address unmet needs in cancer treatment, announced that it has commenced the first human subject dosing with OXL001. This first study is designed to investigate the pharmacokinetics (PK) and safety of various doses of OXL001 in healthy volunteers.

Oxilio’s lead product, OXL001, has been developed utilizing a novel bio-enabling platform technology created by our development partner, TRx Biosciences, and Quotient Sciences' integrated drug development, manufacturing, and clinical testing platform Translational Pharmaceutics®.

Dr. Simon Yaxley, Director of Oxilio, said: “Working together with our partners Quotient Sciences and TRx Biosciences we are pleased to have been able to move rapidly into the clinic following recent approval for this study by the UK Medicines and Healthcare Products Regulatory Agency (MHRA). This is an important milestone for the business, and we look forward to providing the resulting study data at the earliest opportunity.”

Dr. Robin Bannister, CEO of TRx Biosciences, added: “Our work with Oxilio and the unique development challenges in repurposing OXL001 into oncology have resulted in significant advancement of TRx’s underlying technology and we’re delighted to now see the progression of OXL001 into the clinic, given its immense potential as a pan-cancer therapy. We will continue to support Oxilio throughout its clinical development activities, which will further validate our targeted oral delivery platform”

Dr. Mark Egerton, CEO of Quotient Sciences, said: “Quotient Sciences is proud to have helped the Oxilio team achieve this important milestone. Our unique Translational Pharmaceutics® platform allowed us to rapidly progress OXL001 into the clinic and now both Oxilio and TRx Biosciences can make informed decisions based on emerging clinical data to improve the potential of downstream success. We will continue supporting Oxilio with our integrated capabilities to accelerate the development timeline of OXL001, and ultimately get this life-changing therapy to patients faster.” 


About Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast. For more information, please visit quotientsciences.com.

About Oxilio

Oxilio is a pioneering pharmaceutical drug development company improving cancer treatment through rapid, cost-effective drug development. Our mission is to identify, repurpose, and commercialize existing drugs to address unmet needs in cancer therapy. We find new uses for old drugs, a proven approach that involves less risk, time, and cost to bring a drug to the marketplace. Through repurposing, reformulation, and gold-standard modeling and simulations, we are fast-tracking disruptive drug development at speed and at low cost.

Oxilio Company Contact

[email protected]

Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for Emplicure’s First Clinical Pharmacokinetic Study for EMPLI03

Translational Pharmaceutics®

Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for Emplicure’s First Clinical Pharmacokinetic Study for EMPLI03

Quotient Sciences logo

Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for Emplicure’s First Clinical Pharmacokinetic Study for EMPLI03.

NOTTINGHAM, UK; November 29, 2022 – Quotient Sciences, a global drug development and manufacturing accelerator, today announced a partnership with Emplicure, a Swedish pharmaceutical company focused on chronic pain and abuse-deterrent formulations.

The partnership will see Quotient Sciences support the GMP manufacture and first clinical pharmacokinetic (PK) study for EMPLI03 using its unique Translational Pharmaceutics® platform.

Emplicure is developing EMPLI03 as an oral buccal tablet with extended-release properties intended for the treatment of moderate to severe pain. The formulation is also designed to limit the potential for manipulation of the tablet for abuse. 

Quotient Sciences’ integrated Translational Pharmaceutics platform has been used to establish the GMP manufacturing process for EMPLI03 and to perform the first clinical PK study. Dosing in the PK study has been successfully completed, and top-line data will be available at the beginning of 2023.

"We have achieved one of our milestones in the development of a Buprenorphine product for the treatment of moderate to severe pain. With properties that limit abuse, EMPLI03 may contribute to a safer medical treatment", said Håkan Engqvist, CEO of Emplicure.

Mark Egerton, PhD, CEO of Quotient Sciences, added, "We are delighted to partner with Emplicure on the development of a potential treatment for moderate to severe pain. Using our unique Translational Pharmaceutics platform, the GMP manufacturing and first PK study for EMPLI03 has been fully integrated, which is a proven approach to accelerate development timelines."

Quotient Sciences introduced its Translational Pharmaceutics platform in 2008 as a fully integrated drug development and clinical testing platform.

The platform integrates drug substance, drug product, and clinical testing activities under one organization to break down industry silos and accelerate molecules through development.


About Emplicure
Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at emplicure.com.

About Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast. For more information, please contact us.

Download the press release (PDF)

Eleanor Row: Discovery to IND - SpeakPharma

Articles & Publications , Eleanor Row

Eleanor Row: Discovery to IND - SpeakPharma

Eleanor Row

Over the past 30 years, Quotient Sciences has worked on over 3,000 molecules across all stages of development. SpeakPharma interviews Eleanor Row, our Executive Director of Commercial who discusses the challenges that drug developers should be aware of when trying to quickly get their molecule from discovery to investigational new drug (IND) stage - and onward into the clinic.

Eleanor also talks about how our integrated approach can help accelerate a molecule’s pathway to IND and beyond while sheding light on the different development functions at an early stage of drug development.

Read more of Eleanor's SpeakPharma interview on the Pharma Compass website by following the link below.

Continue Reading

Subscribe to